AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Akebia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.68+0.01 (+1.51%)
Close on Oct 19, 2026
- Market cap
- $183.36M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.2499 (−76.79%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Akebia Therapeutics, Inc. grew revenue 7.5% to $219.06M over the twelve months to Jun 30, 2026. Operating income fell 2012.3% to -$15.13M, moving the operating margin from 0.4% to -6.9%. Free cash flow was $40.26M.
Revenue
$219.06M
+7.5% vs. a year earlier
Operating income
-$15.13M
-2012.3% vs. a year earlier
Free cash flow
$40.26M
TTM Q2 2026
EPS, diluted
-$0.11
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $183.36M
- P/E ratio
- –
- Price to sales
- 0.84
- Price to book
- 7.33
- Dividend yield
- –
- Free cash flow yield
- 21.96%
Fundamentals
- Revenue
- $219.06M
- Net income
- -$29.67M
- EPS, diluted
- -$0.11
- Free cash flow
- $40.26M
- Book value per share
- $0.09
- Diluted shares
- 270M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$219.06M+7.5% YoY
Gross profit
$174.43M+15.0% YoY
Operating income
-$15.13M-2012.3% YoY
Net income
-$29.67M
EPS, diluted
-$0.11
Free cash flow
$40.26M
Reported periodTrailing twelve months